Aim: There is a large body of evidence of clinical studies regarding the relation between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men. A possible link between inflammation and these 2 clinical entities has also been proposed. Here, we aimed at evaluating the role of neutrophil-lymphocyte ratio (NLR), an indicator of inflammation and MetS, in the pathogenesis of LUTS and other BPH-related parameters. Method: We evaluated 244 patients with benign prostate hyperplasia admitted to our outpatient clinic between January 2014 and June 2015. NLR was calculated from the peripheral blood sample for all patients. Patients' anthropometric characteristics, serum lipid levels, waist circumferences, total prostate-specific antigen (PSA) and testosterone values, prostate volumes, max values and International Prostate Symptom Score (IPSS) were recorded. All statistical analyses were conducted by SPSS version 17.0 package program, and p value <0.05 was chosen as the criterion for statistical significance. Results: There was statistical significance between NLR and patients with severe IPSS score (>20) and over age 60 years (p = 0.02). Patients younger than 60 years had statistical significance between NLR and PSA <2.5 ng/dl (p = 0.004). When body mass index was selected, there was statistical significance between prostate volume <35 ml (p = 0.009) and age >60 years (p = 0.028). If 60 years of age was selected as cut-off value, there is statistical significance between age and severe IPSS, and in terms of mild erectile dysfunction, PSA >2.5 ng/dl, and prostate volume >35 ml. Conclusion: We found positive correlation between NLR and severe symptoms and progression of BPH. In this manner, anti-inflammatory therapy could contribute to the medical treatment of BPH. Higher NLR may be a candidate marker for severity of symptoms in BPH patients.

Keywords:
Benign prostate hyperplasia, Metabolic syndrome, Neutrophil-lymphocyte ratio, Lower urinary tract symptoms
1.
McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care 2006;12(5 suppl):S122-S128.
2.
Parsons JK, Bergstrom J, Barrett-Connor E: Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008;101:313-318.
3.
Caine M, Raz S, Zeigler M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975;47:193-202.
4.
Roehrborn C, Siami P, Barkin J, et al; CombAT Study Group: The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-621; discussion 621.
5.
Lepor H, Williford WO, Barry MJ, et al: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med 1996;335:533-539.
6.
Riehmann M, Knes JM, Heisey D, et al: Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995;45:768-775.
7.
Roehrborn CG: BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008;101(suppl 3):17-21.
8.
Chughtai B, Lee R, Te A, Kaplan S: Role of inflammation in benign prostatic hyperplasia. Rev Urol 2011;13:147-150.
9.
Ficarra V, Sekulovic S, Zattoni F, Zazzera M, Novara G: Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl 2013;12:110-115.
10.
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al: Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 2014;66:619-622.
11.
DiBello JR, Ioannou C, Rees J, Challacombe B, Maskell J, Choudhury N, et al: Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study. BJU Int 2016;117:801-808.
12.
Zou C, Gong D, Fang N, Fan Y: Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol 2016;34:281-289.
13.
Yin Z, Yang JR, Rao JM, Song W, Zhou KQ: Association between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men. Asian J Androl 2015;17:826-830.
14.
Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, et al: Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int 2015;115:24-31.
15.
Balta S, Celik T, Mikhailidis DP, Ozturk C, Demirkol S, Aparci M, et al: The relation between atherosclerosis and the neutrophil-lymphocyte ratio. Clin Appl Thromb Hemost 2016;22:405-411.
16.
Yasar Z, Buyuksirin M, Ucsular FD, Kargı A, Erdem F, Talay F, et al: Is an elevated neutrophil-to-lymphocyte ratio a predictor of metabolic syndrome in patients with chronic obstructive pulmonary disease? Eur Rev Med Pharmacol Sci 2015;19:956-962.
17.
Buyukkaya E, Karakas MF, Karakas E, Akçay AB, Tanboga IH, Kurt M, et al: Correlation of neutrophil to lymphocyte ratio with the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost 2014;20:159-163.
18.
Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al: Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109:416-421.
19.
Walsh SR, Cook EJ, Goulder F, et al: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181-184.
20.
Tamhane UU, Aneja S, Montgomery D, et al: Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008;102:653-657.
21.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-2497.
22.
Gandaglia G, Briganti A, Gontero P, et al: The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432-441.
23.
Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A: Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl 2009;8:879-886.
24.
Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS: The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008;54:1379-1384.
25.
Robert G, Descazeaud A, Nicolaïew N, et al: Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009;69:1774-1780.
26.
Norström MM, Rådestad E, Sundberg B, Mattsson J, Henningsohn L, Levitsky V, et al: Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget 2016, Epub ahead of print.
27.
Oelke M, Bachmann A, Descazeaud A, et al: Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology, 2012.
28.
Kahokehr A, Vather R, Nixon A, Hill AG: Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int 2013;111:304-311.
29.
Tanik S, Albayrak S, Zengin K, Borekci H, Bakirtas H, Imamoglu MA, et al: Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev 2014;15:6375-6379.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.